ETON
Eton Pharmaceuticals, Inc.
Price Chart
Latest Quote
$33.45
+0.97 (+2.99%)
Current Price
| Previous Close | $32.48 |
| Open | $32.91 |
| Day High | $33.48 |
| Day Low | $32.48 |
| Volume | 9,641 |
Stock Information
| Shares Outstanding | 27.39M |
| Total Debt | $31.26M |
| Cash Equivalents | $19.66M |
| Revenue | $86.93M |
| Net Income | $-1.48M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $916.30M |
| EPS (TTM) | $-0.06 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $901.30M |
| Sales | $86.93M |
| Income | $-1.48M |
| Book/sh | $1.12 |
| Cash/sh | $0.72 |
| Employees | 44 |
Financial Ratios
| Quick Ratio | 0.75 |
| Current Ratio | 1.21 |
| Debt/Eq | 102.11 |
Returns & Margins
| ROA | 4.76% |
| ROE | -5.36% |
| Gross Margin | 59.72% |
| Operating Margin | 11.39% |
| Profit Margin | -1.70% |
Ownership
| Insider Ownership | 4.45% |
| Institutional Ownership | 65.41% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 17.79 |
| P/S | 10.54 |
| P/B | 29.89 |
Analyst Data
| Recommendation | none |
| Target Price | $45.67 |
Technical Indicators
| SMA20 | $30.93 |
| SMA50 | $29.08 |
| SMA200 | $20.79 |
| RSI | 76.71 |
| ATR | 1.5350 |
| Shares Float | 21.13M |
| Short Float | 6.47% |
| Short Ratio | 2.83 |
| Volatility | 0.89 |
| Rel Volume | 0.03 |
Performance History
| Week | +5.89% |
| Month | -2.90% |
| Quarter | +49.87% |
| 6 Months | +111.45% |
| YTD | +105.73% |
| Year | +144.17% |
| 3 Years | +818.98% |
| 5 Years | +413.05% |
| 10 Years | +435.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $33.45 | 9,641 |
| 2026-06-18 | $32.48 | 612,800 |
| 2026-06-17 | $32.76 | 341,800 |
| 2026-06-16 | $32.35 | 187,600 |
| 2026-06-15 | $32.15 | 265,900 |
| 2026-06-12 | $31.59 | 206,800 |
| 2026-06-11 | $32.11 | 263,600 |
| 2026-06-10 | $30.95 | 265,600 |
| 2026-06-09 | $30.53 | 219,100 |
| 2026-06-08 | $29.95 | 499,000 |
| 2026-06-05 | $29.13 | 239,000 |
| 2026-06-04 | $28.90 | 722,000 |
| 2026-06-03 | $27.61 | 332,000 |
| 2026-06-02 | $27.40 | 422,400 |
| 2026-06-01 | $28.68 | 393,400 |
| 2026-05-29 | $30.45 | 376,500 |
| 2026-05-28 | $31.86 | 398,300 |
| 2026-05-27 | $32.40 | 443,400 |
| 2026-05-26 | $31.29 | 361,100 |
| 2026-05-22 | $32.59 | 523,700 |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
đ° Latest News
H.C. Wainwright Remains Bullish on Eton Pharmaceuticalsâ (ETON) Growth Strategy
Insider Monkey âĸ 2026-05-23T12:16:09Z
Stock Market Leaders Respect The 21-Day Line. You Should Too.
Investor's Business Daily âĸ 2026-05-22T14:32:28Z
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next
Simply Wall St. âĸ 2026-05-16T14:33:09Z
Eton (ETON) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-15T17:21:48Z
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T12:30:00Z
Eton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ...
GuruFocus.com âĸ 2026-05-15T05:02:09ZEton Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-15T00:05:46Z
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Zacks âĸ 2026-05-14T21:30:02Z
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T19:25:01Z
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T21:10:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $37,210,000 | $15,600,000 | $10,581,000 | $6,933,000 |
| Cost Of Revenue | $37,210,000 | $15,600,000 | $10,581,000 | $6,933,000 |
| Total Revenue | $79,950,000 | $39,011,000 | $31,642,000 | $21,251,000 |
| Operating Revenue | $79,950,000 | $39,011,000 | $31,642,000 | $21,251,000 |
| Expenses | ||||
| Total Expenses | $80,794,000 | $41,608,000 | $32,834,000 | $29,511,000 |
| Net Non Operating Interest Income Expense | $-3,714,000 | $-1,211,000 | $503,000 | $-761,000 |
| Total Other Finance Cost | $3,714,000 | $1,211,000 | $-503,000 | $761,000 |
| Operating Expense | $43,584,000 | $26,008,000 | $22,253,000 | $22,578,000 |
| General And Administrative Expense | $35,819,000 | $22,753,000 | $18,931,000 | $18,582,000 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Net Interest Income | $-3,714,000 | $-1,211,000 | $503,000 | $-761,000 |
| Normalized Income | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Net Income From Continuing And Discontinued Operation | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Total Operating Income As Reported | $-844,000 | $-2,597,000 | $-1,192,000 | $-8,260,000 |
| Net Income Common Stockholders | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Net Income | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Net Income Including Noncontrolling Interests | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Net Income Continuous Operations | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Pretax Income | $-4,558,000 | $-3,808,000 | $-689,000 | $-9,021,000 |
| Operating Income | $-844,000 | $-2,597,000 | $-1,192,000 | $-8,260,000 |
| Gross Profit | $42,740,000 | $23,411,000 | $21,061,000 | $14,318,000 |
| Special Income Charges | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.17 | $-0.15 | $-0.04 | $-0.36 |
| Basic EPS | $-0.17 | $-0.15 | $-0.04 | $-0.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $3,200,000 | $-1,451,000 | $-291,000 | $-6,486,000 |
| Reconciled Depreciation | $4,044,000 | $1,146,000 | $901,000 | $1,774,000 |
| EBITDA (Bullshit earnings) | $3,200,000 | $-1,451,000 | $-291,000 | $-6,486,000 |
| EBIT | $-844,000 | $-2,597,000 | $-1,192,000 | $-8,260,000 |
| Diluted Average Shares | $26,908,000 | $25,895,000 | $25,645,000 | $25,146,000 |
| Basic Average Shares | $26,908,000 | $25,895,000 | $25,645,000 | $25,146,000 |
| Diluted NI Availto Com Stockholders | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Tax Provision | $43,000 | $15,000 | $247,000 | $0 |
| Research And Development | $7,765,000 | $3,255,000 | $3,322,000 | $3,996,000 |
| Selling General And Administration | $35,819,000 | $22,753,000 | $18,931,000 | $18,582,000 |
| Other Gand A | $35,819,000 | $22,753,000 | $18,931,000 | $18,582,000 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
| Gain On Sale Of Ppe | - | - | $0 | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,724,000 | $-10,453,000 | $10,738,000 | $8,324,000 |
| Total Assets | $92,114,000 | $76,123,000 | $31,740,000 | $25,030,000 |
| Total Non Current Assets | $31,533,000 | $35,102,000 | $4,901,000 | $5,026,000 |
| Other Non Current Assets | $19,000 | $12,000 | $12,000 | $12,000 |
| Goodwill And Other Intangible Assets | $30,878,000 | $34,881,000 | $4,739,000 | $4,754,000 |
| Current Assets | $60,581,000 | $41,021,000 | $26,839,000 | $20,004,000 |
| Other Current Assets | $7,463,000 | $5,492,000 | $1,129,000 | $1,290,000 |
| Inventory | $15,419,000 | $15,232,000 | $911,000 | $557,000 |
| Receivables | $11,757,000 | $5,361,000 | $3,411,000 | $1,852,000 |
| Accounts Receivable | $11,757,000 | $5,361,000 | $3,411,000 | $1,852,000 |
| Allowance For Doubtful Accounts Receivable | $-272,000 | $-238,000 | $-129,000 | $-262,000 |
| Gross Accounts Receivable | $12,029,000 | $5,599,000 | $3,540,000 | $2,114,000 |
| Cash Cash Equivalents And Short Term Investments | $25,942,000 | $14,936,000 | $21,388,000 | $16,305,000 |
| Cash And Cash Equivalents | $25,942,000 | $14,936,000 | $21,388,000 | $16,305,000 |
| Other Intangible Assets | - | - | - | $4,754,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $4,616,000 | $14,875,000 | - | - |
| Total Debt | $31,018,000 | $29,918,000 | $5,402,000 | $6,524,000 |
| Long Term Debt And Capital Lease Obligation | $22,229,000 | $29,918,000 | $22,000 | $5,491,000 |
| Long Term Debt | $21,769,000 | $29,811,000 | - | $5,384,000 |
| Current Debt And Capital Lease Obligation | $8,789,000 | - | $5,380,000 | $1,033,000 |
| Current Debt | $8,789,000 | - | $5,380,000 | $1,033,000 |
| Other Current Borrowings | - | - | $5,380,000 | $1,033,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $65,960,000 | $51,695,000 | $16,263,000 | $11,952,000 |
| Total Non Current Liabilities Net Minority Interest | $27,470,000 | $31,748,000 | $22,000 | $5,491,000 |
| Other Non Current Liabilities | $5,241,000 | $1,830,000 | - | - |
| Current Liabilities | $38,490,000 | $19,947,000 | $16,241,000 | $6,461,000 |
| Payables And Accrued Expenses | $29,701,000 | $19,947,000 | $10,861,000 | $5,428,000 |
| Payables | $10,976,000 | $4,167,000 | $1,848,000 | $1,766,000 |
| Accounts Payable | $10,976,000 | $4,167,000 | $1,848,000 | $1,766,000 |
| Equity | ||||
| Common Stock Equity | $26,154,000 | $24,428,000 | $15,477,000 | $13,078,000 |
| Total Equity Gross Minority Interest | $26,154,000 | $24,428,000 | $15,477,000 | $13,078,000 |
| Stockholders Equity | $26,154,000 | $24,428,000 | $15,477,000 | $13,078,000 |
| Retained Earnings | $-112,494,000 | $-107,893,000 | $-104,070,000 | $-103,134,000 |
| Other | ||||
| Ordinary Shares Number | $27,047,061 | $26,709,084 | $25,688,062 | $25,353,119 |
| Share Issued | $27,047,061 | $26,709,084 | $25,688,062 | $25,353,119 |
| Tangible Book Value | $-4,724,000 | $-10,453,000 | $10,738,000 | $8,324,000 |
| Invested Capital | $56,712,000 | $54,239,000 | $20,857,000 | $19,495,000 |
| Working Capital | $22,091,000 | $21,074,000 | $10,598,000 | $13,543,000 |
| Capital Lease Obligations | $460,000 | $107,000 | $22,000 | $107,000 |
| Total Capitalization | $47,923,000 | $54,239,000 | $15,477,000 | $18,462,000 |
| Additional Paid In Capital | $138,621,000 | $132,294,000 | $119,521,000 | $116,187,000 |
| Capital Stock | $27,000 | $27,000 | $26,000 | $25,000 |
| Common Stock | $27,000 | $27,000 | $26,000 | $25,000 |
| Long Term Capital Lease Obligation | $460,000 | $107,000 | $22,000 | $107,000 |
| Current Accrued Expenses | $18,725,000 | $15,780,000 | $9,013,000 | $3,662,000 |
| Net PPE | $636,000 | $209,000 | $150,000 | $260,000 |
| Accumulated Depreciation | $-486,000 | $-446,000 | $-395,000 | $-352,000 |
| Gross PPE | $1,122,000 | $655,000 | $545,000 | $612,000 |
| Leases | $295,000 | $103,000 | $103,000 | $71,000 |
| Other Properties | $52,000 | $52,000 | $52,000 | $52,000 |
| Machinery Furniture Equipment | $465,000 | $325,000 | $298,000 | $289,000 |
| Buildings And Improvements | $310,000 | $175,000 | $92,000 | $188,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-1,199,000 | $-605,000 | - | - |
| Finished Goods | $6,630,000 | $7,194,000 | - | - |
| Work In Process | $9,431,000 | $3,288,000 | - | - |
| Raw Materials | $557,000 | $5,355,000 | - | - |
| Treasury Shares Number | - | - | $0 | - |
| Construction In Progress | - | - | $0 | $12,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $10,191,000 | $-9,045,000 | $6,040,000 | $2,033,000 |
| Operating Activities | ||||
| Operating Cash Flow | $10,524,000 | $969,000 | $6,815,000 | $4,821,000 |
| Cash Flow From Continuing Operating Activities | $10,524,000 | $969,000 | $6,815,000 | $4,821,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-333,000 | $-10,014,000 | $-775,000 | $-2,788,000 |
| Investing Cash Flow | $-333,000 | $-40,014,000 | $-775,000 | $-2,788,000 |
| Cash Flow From Continuing Investing Activities | $-333,000 | $-40,014,000 | $-775,000 | $-2,788,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $7,000,000 | $0 | $0 |
| Financing Cash Flow | $815,000 | $32,593,000 | $-957,000 | $-134,000 |
| Cash Flow From Continuing Financing Activities | $815,000 | $32,593,000 | $-957,000 | $-134,000 |
| Net Common Stock Issuance | $0 | $7,000,000 | $0 | $0 |
| Common Stock Issuance | $0 | $7,000,000 | $0 | $0 |
| Net Other Financing Charges | - | - | $-180,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $-1,155,000 | $-1,155,000 | $-385,000 |
| Issuance Of Debt | $0 | $25,309,000 | $0 | $0 |
| Interest Paid Supplemental Data | $3,325,000 | $665,000 | $842,000 | $730,000 |
| Income Tax Paid Supplemental Data | $118,000 | $82,000 | $247,000 | $0 |
| End Cash Position | $25,942,000 | $14,936,000 | $21,388,000 | $16,305,000 |
| Beginning Cash Position | $14,936,000 | $21,388,000 | $16,305,000 | $14,406,000 |
| Changes In Cash | $11,006,000 | $-6,452,000 | $5,083,000 | $1,899,000 |
| Proceeds From Stock Option Exercised | $815,000 | $1,439,000 | $378,000 | $251,000 |
| Net Issuance Payments Of Debt | $0 | $24,154,000 | $-1,155,000 | $-385,000 |
| Net Long Term Debt Issuance | $0 | $24,154,000 | $-1,155,000 | $-385,000 |
| Long Term Debt Payments | $0 | $-1,155,000 | $-1,155,000 | $-385,000 |
| Long Term Debt Issuance | $0 | $25,309,000 | $0 | $0 |
| Net Business Purchase And Sale | $0 | $-30,000,000 | $0 | $0 |
| Purchase Of Business | $0 | $-30,000,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-9,988,000 | $-775,000 | $-2,750,000 |
| Purchase Of Intangibles | $0 | $-9,988,000 | $-775,000 | $-2,750,000 |
| Net PPE Purchase And Sale | $-333,000 | $-26,000 | $0 | $-38,000 |
| Purchase Of PPE | $-333,000 | $-26,000 | $0 | $-38,000 |
| Change In Working Capital | $-859,000 | $-1,227,000 | $3,514,000 | $7,661,000 |
| Change In Other Working Capital | $3,114,000 | $38,000 | - | - |
| Change In Payables And Accrued Expense | $10,270,000 | $7,041,000 | $5,348,000 | $2,209,000 |
| Change In Accrued Expense | $3,462,000 | $4,723,000 | $5,295,000 | $2,217,000 |
| Change In Payable | $6,808,000 | $2,318,000 | $53,000 | $-8,000 |
| Change In Account Payable | $6,808,000 | $2,318,000 | $53,000 | $-8,000 |
| Change In Prepaid Assets | $-1,971,000 | $-3,349,000 | $94,000 | $1,840,000 |
| Change In Inventory | $-5,876,000 | $-1,839,000 | $-369,000 | $-7,000 |
| Change In Receivables | $-6,396,000 | $-3,118,000 | $-1,559,000 | $3,619,000 |
| Changes In Account Receivables | $-6,396,000 | $-3,118,000 | $-1,559,000 | $3,619,000 |
| Other Non Cash Items | $5,834,000 | $1,179,000 | $184,000 | $189,000 |
| Stock Based Compensation | $5,512,000 | $3,165,000 | $3,137,000 | $4,218,000 |
| Provisionand Write Offof Assets | $594,000 | $529,000 | $15,000 | - |
| Depreciation Amortization Depletion | $4,044,000 | $1,146,000 | $901,000 | $1,774,000 |
| Depreciation And Amortization | $4,044,000 | $1,146,000 | $901,000 | $1,774,000 |
| Net Income From Continuing Operations | $-4,601,000 | $-3,823,000 | $-936,000 | $-9,021,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
Fetched: 2026-06-17